AU2007280282B2 - Method for predicting protein aggregation and designing aggregation inhibitors - Google Patents

Method for predicting protein aggregation and designing aggregation inhibitors Download PDF

Info

Publication number
AU2007280282B2
AU2007280282B2 AU2007280282A AU2007280282A AU2007280282B2 AU 2007280282 B2 AU2007280282 B2 AU 2007280282B2 AU 2007280282 A AU2007280282 A AU 2007280282A AU 2007280282 A AU2007280282 A AU 2007280282A AU 2007280282 B2 AU2007280282 B2 AU 2007280282B2
Authority
AU
Australia
Prior art keywords
protein
aggregation
peptide
residues
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007280282A
Other languages
English (en)
Other versions
AU2007280282A1 (en
Inventor
Kai J. Kohlhoff
Michele Vendruscolo
Jesus Zurdo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Biologics PLC
Original Assignee
Lonza Biologics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics PLC filed Critical Lonza Biologics PLC
Publication of AU2007280282A1 publication Critical patent/AU2007280282A1/en
Application granted granted Critical
Publication of AU2007280282B2 publication Critical patent/AU2007280282B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
AU2007280282A 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors Ceased AU2007280282B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82155306P 2006-08-04 2006-08-04
US60/821,553 2006-08-04
PCT/GB2007/002789 WO2008015384A1 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Publications (2)

Publication Number Publication Date
AU2007280282A1 AU2007280282A1 (en) 2008-02-07
AU2007280282B2 true AU2007280282B2 (en) 2012-02-02

Family

ID=38573441

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007280282A Ceased AU2007280282B2 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Country Status (11)

Country Link
US (1) US8290713B2 (enExample)
EP (1) EP2047393A1 (enExample)
JP (1) JP2009545756A (enExample)
KR (1) KR20090047470A (enExample)
CN (1) CN101501694B (enExample)
AU (1) AU2007280282B2 (enExample)
CA (1) CA2657847A1 (enExample)
EA (1) EA016884B1 (enExample)
IL (1) IL196551A (enExample)
SG (1) SG173405A1 (enExample)
WO (1) WO2008015384A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
GB2455102A (en) * 2007-11-28 2009-06-03 Cambridge Entpr Ltd Protein Aggregation Prediction Systems
EP2278998A1 (en) 2008-04-17 2011-02-02 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN110187119B (zh) * 2008-10-31 2022-07-29 耶鲁大学 子痫前期检测和治疗的方法和组合物
WO2011047442A1 (en) * 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120108904A1 (en) * 2010-10-20 2012-05-03 Yong Ma Cleaner for endoscope
CN103772487B (zh) * 2012-10-24 2015-11-25 国家纳米科学中心 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
CN104502219B (zh) * 2014-12-18 2017-09-29 江苏大学 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法
SG11201705275VA (en) * 2015-01-06 2017-07-28 Univ North Carolina State Modeling ribosome dynamics to optimize heterologous protein production
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
BR112018014870A2 (pt) * 2016-01-21 2018-12-11 Protein Dynamic Solutions Llc método e sistema para análise de dados espectrais
US10815271B2 (en) * 2016-06-29 2020-10-27 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
CN106501550A (zh) * 2016-12-09 2017-03-15 江苏大学 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法
CN111653310B (zh) * 2020-06-29 2023-06-20 北京大学深圳研究生院 含二硫键多肽的结构预测方法及装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004739B1 (ru) * 1999-11-05 2004-08-26 Эксоникс, Инк. ПЕПТИДНЫЕ АНАЛОГИ И МИМЕТИКИ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ IN VIVO ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АНОМАЛЬНОЙ УКЛАДКОЙ БЕЛКОВ В АМИЛОИДНЫЕ ИЛИ АМИЛОИДПОДОБНЫЕ ОТЛОЖЕНИЯ, ИЛИ ИХ ПАТОЛОГИЧЕСКИЕ ПРЕДШЕСТВЕННИКИ, ОБОГАЩЕННЫЕ b-СКЛАДКАМИ
EP1646375A2 (en) * 2003-06-23 2006-04-19 Neurochem (International) Limited Treatment of protein aggregation disorders
GB0325817D0 (en) 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE GROOT NATALIA SÁNCHEZ ET AL: "Prediction of hot spots of aggregation in disease-linked polypeptides" BMC STRUCTURAL BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 5, no. 1, 30 September 2005 (2005-09-30), page 18 *
PAWAR, A P et al.: "Prediction of "Aggregation-prone" and "Aggregation-susceptible" Regions in Proteins Associated with Neurodegenerative Diseases" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 350, no. 2,8 July 2005, pages 379-392 *

Also Published As

Publication number Publication date
IL196551A (en) 2013-01-31
SG173405A1 (en) 2011-08-29
EA016884B1 (ru) 2012-08-30
KR20090047470A (ko) 2009-05-12
EP2047393A1 (en) 2009-04-15
CN101501694A (zh) 2009-08-05
US8290713B2 (en) 2012-10-16
JP2009545756A (ja) 2009-12-24
CA2657847A1 (en) 2008-02-07
WO2008015384A1 (en) 2008-02-07
HK1131239A1 (en) 2010-01-15
AU2007280282A1 (en) 2008-02-07
CN101501694B (zh) 2011-11-30
US20100160602A1 (en) 2010-06-24
IL196551A0 (en) 2009-11-18
WO2008015384A8 (en) 2008-05-15
EA200970180A1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
AU2007280282B2 (en) Method for predicting protein aggregation and designing aggregation inhibitors
Murray et al. De novo designed protein inhibitors of amyloid aggregation and seeding
Samantray et al. Different force fields give rise to different amyloid aggregation pathways in molecular dynamics simulations
Yoon et al. Detecting hidden sequence propensity for amyloid fibril formation
Sommer et al. Structure-guided isoform identification for the human transcriptome
Fatafta et al. A brief history of amyloid aggregation simulations
Pujols et al. A3D 2.0 update for the prediction and optimization of protein solubility
Linh et al. Impact of mutations at C-terminus on structures and dynamics of Aβ40 and Aβ42: a molecular simulation study
Kardos et al. Phosphorylation as conformational switch from the native to amyloid state: Trp-cage as a protein aggregation model
Sari et al. Hairpin trimer transition state of amyloid fibril
Huang et al. Unveiling medin folding and dimerization dynamics and conformations via atomistic discrete molecular dynamics simulations
Black et al. Evaluating calmodulin–protein interactions by rapid photoactivated cross-linking in live cells metabolically labeled with photo-methionine
Li et al. Unraveling the interplay of extracellular domain conformational changes and parathyroid hormone type 1 receptor activation in class B1 G protein-coupled receptors: integrating enhanced sampling molecular dynamics simulations and markov state models
Li et al. Simple and Effective Conformational Sampling Strategy for Intrinsically Disordered Proteins Using the UNRES Web Server
Wang et al. StaPep: An open-source toolkit for structure prediction, feature extraction, and rational design of hydrocarbon-stapled peptides
Balakrishnan et al. Engineering Aromatic–Aromatic Interactions To Nucleate Folding in Intrinsically Disordered Regions of Proteins
Jakubek et al. Polyglutamine solution-state structural propensity is repeat length dependent
Suladze et al. Structural Insights into Seeding Mechanisms of hIAPP Fibril Formation
Puławski et al. Multiscale modeling of protofilament structures: A case study on insulin amyloid aggregates
Liang et al. Structures and Dynamics of β-Rich Oligomers of ATTR (105–115) Assembly
Betancourt A reduced protein model with accurate native‐structure identification ability
Pantoja-Uceda et al. The NMR structure and dynamics of the two-domain tick carboxypeptidase inhibitor reveal flexibility in its free form and stiffness upon binding to human carboxypeptidase B
HK1131239B (en) Method for predicting protein aggregation and designing aggregation inhibitors
Rea et al. Mechanism of ligand-induced folding of a natively unfolded helixless variant of rabbit I-BABP
Duan et al. Performance of Hybrid Strategies Combining MDockPP and AlphaFold2 in CAPRI Rounds 47–55

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired